Evidence map›Paper›PMID 39678231›Full record

ReviewInfectious medicine2024

Vagal nerve stimulation for the management of long COVID symptoms.

Malik W Z Khan, Muhammad Ahmad, Salma Qudrat, Fatma Afridi, Najia Ali Khan, Zain Afridi, Fahad, Touba Azeem, Jibran Ikram

Abstract readReview
In one paragraph

Review in Infectious medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. The brain and heart-axis in neurodegeneration and cardiovascular disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Neuroimmune Control of Inflammation in Acute Kidney Injury and Multiorgan Dysfunction.Journal of the American Society of Nephrology : JASN · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Malik W Z KhanYale University School of Medicine, New Haven, Connecticut 06520, USA.
Muhammad AhmadKhyber Medical College, Peshawar 25120, Khyber Pakhtunkhwa, Pakistan.
Salma QudratKhyber Medical College, Peshawar 25120, Khyber Pakhtunkhwa, Pakistan.
Fatma AfridiKhyber Medical College, Peshawar 25120, Khyber Pakhtunkhwa, Pakistan.
Najia Ali KhanKhyber Medical College, Peshawar 25120, Khyber Pakhtunkhwa, Pakistan.
Zain AfridiKhyber Medical College, Peshawar 25120, Khyber Pakhtunkhwa, Pakistan.
FahadKhyber Medical College, Peshawar 25120, Khyber Pakhtunkhwa, Pakistan.
Touba AzeemKhyber Medical College, Peshawar 25120, Khyber Pakhtunkhwa, Pakistan.
Jibran IkramDepartment of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review investigates the therapeutic potential of vagal nerve stimulation (VNS) in managing long COVID, a condition marked by persistent symptoms following acute SARS-CoV-2 infection. Long COVID manifests as ongoing fatigue, cognitive impairment, and autonomic dysfunction, hypothesized to arise from sustained inflammatory and neurological dysregulation. The vagus nerve, central to modulating systemic inflammation and autonomic homeostasis, represents a promising therapeutic target for symptom alleviation through VNS. A comprehensive literature search was conducted across PubMed, Scopus, and Web of Science to identify studies evaluating VNS in the context of long COVID. Preliminary evidence from small-scale pilot studies suggests VNS may attenuate systemic inflammation through activation of the cholinergic anti-inflammatory pathway (CAP), thus restoring autonomic balance and ameliorating symptoms such as fatigue, cognitive dysfunction, and anxiety. In targeting the inflammatory cascade that underlies both acute COVID-19 pathophysiology and its prolonged sequelae, VNS holds potential as an innovative intervention for persistent post-viral symptoms. While these initial findings indicate promise, current data remain limited in scope and robustness, underscoring the need for larger, controlled trials to validate the efficacy and mechanisms of VNS in long COVID management. Establishing a clearer understanding of VNS's impact on inflammation and autonomic regulation in this context is crucial to inform clinical guidelines and therapeutic strategies for long COVID, potentially offering a targeted approach for mitigating this disabling condition.

Indexed as

COVID-19Invasive vagal nerve stimulationLong COVIDNon-invasive vagal nerve stimulationTranscutaneous vagal nerve stimulation

Identifiers

PMID39678231
PMCPMC11638592

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.